<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390650</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5581</org_study_id>
    <secondary_id>SR48968</secondary_id>
    <nct_id>NCT00390650</nct_id>
  </id_info>
  <brief_title>A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder</brief_title>
  <official_title>An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to
      placebo in patients with generalized anxiety disorder. The secondary objectives are to
      evaluate the efficacy of saredutant on disability and quality of life in patients with
      generalized anxiety disorder, and to evaluate blood levels of saredutant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The key secondary efficacy outcome is change from baseline in the Clinical Global Impression Severity of Illness score.</measure>
  </secondary_outcome>
  <enrollment type="Actual">366</enrollment>
  <condition>Anxiety</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saredutant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of generalized anxiety disorder as defined by Diagnostic and Statistical
             Manual of Mental Disorders (DSM-IV-TR) criteria and confirmed by the Mini
             International Neuropsychiatric Interview (MINI) Plus Generalized Anxiety Disorder
             module.

        Exclusion Criteria:

          -  Total score of less than 22 on the HAM-A.

          -  Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than 18.

          -  Patients with a current history (within 6 months) of major depressive disorder or
             history or presence of bipolar disorders or psychotic disorders.

          -  Patients with alcohol dependence or abuse or substance dependence or abuse in the past
             12 months except nicotine or caffeine dependence.

          -  Patients who have used the following prior to entry into Acute Phase: antipsychotics
             within 3 months, antidepressants including Monoamine Oxidase Inhibitors (MAOIs) within
             1 month, anxiolytics within 2 weeks, mood-stabilizer (lithium, anticonvulsants) within
             1 month, and/or high dose or prolonged benzodiazepine (continuous use for 3 months
             prior to admission) use.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie TRAD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2006</study_first_submitted>
  <study_first_submitted_qc>October 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2006</study_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>clinical trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

